| Psoriasis vulgaris
Enstilar vs Sotyktu
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Enstilar vs Sotyktu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSotyktu has a higher rate of injection site reactions vs Enstilar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sotyktu but not Enstilar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enstilar
Sotyktu
At A Glance
Topical
Once daily
Vitamin D3 analog + corticosteroid
Oral
Daily
TYK2 inhibitor
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Arthritis, Psoriatic
Dosing
Psoriasis vulgaris Apply to affected areas once daily for up to 4 weeks; maximum dose not to exceed 60 g every 4 days; rub in gently; do not use with occlusive dressings, on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Contraindications
—
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
Adverse Reactions
Postmarketing Application site burning, atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure.
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Pharmacology
Enstilar Foam combines calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; exact mechanisms of action in the treatment of plaque psoriasis are unknown.
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enstilar
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (10/12) · Qty limit (9/12)
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Enstilar
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (3/8)
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Enstilar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$30/fillfill
Leo Copay Savings Card: EnstilarCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnstilarView full Enstilar profile
SotyktuView full Sotyktu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.